Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DRRX NASDAQ:ITRM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRRXDURECT$1.91$1.91$0.48▼$2.64$59.31M0.92699,433 shsN/AITRMIterum Therapeutics$0.03$0.03$0.03▼$1.42$1.60M2.964.85 million shsN/A(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRRXDURECT0.00%0.00%0.00%0.00%+176.01%ITRMIterum Therapeutics0.00%0.00%0.00%-82.12%-96.97%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRRXDURECT$1.91$1.91$0.48▼$2.64$59.31M0.92699,433 shsN/AITRMIterum Therapeutics$0.03$0.03$0.03▼$1.42$1.60M2.964.85 million shsN/A(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRRXDURECT0.00%0.00%0.00%0.00%+176.01%ITRMIterum Therapeutics0.00%0.00%0.00%-82.12%-96.97%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDRRXDURECT 2.00HoldN/AN/AITRMIterum Therapeutics 1.67ReduceN/AN/ACurrent Analyst Ratings BreakdownLatest ITRM and DRRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/30/2026ITRMIterum Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold(Data available from 6/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDRRXDURECT$1.66M35.80N/AN/A$0.29 per share6.59ITRMIterum Therapeutics$390K4.10N/AN/A($0.15) per share-0.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDRRXDURECT-$8.32M-$0.10N/AN/AN/A-96.19%-259.16%-71.78%N/AITRMIterum Therapeutics-$24.77M-$0.75N/AN/AN/AN/AN/A-65.54%N/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDRRXDURECTN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDRRXDURECTN/A0.980.95ITRMIterum TherapeuticsN/A2.131.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDRRXDURECT28.03%ITRMIterum Therapeutics9.21%Insider OwnershipCompanyInsider OwnershipDRRXDURECT3.20%ITRMIterum Therapeutics2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDRRXDURECT8031.05 million30.06 millionOptionableITRMIterum Therapeutics1053.29 million52.23 millionNot OptionableITRM and DRRX HeadlinesRecent News About These CompaniesHC Wainwright & Co. downgrades Iterum Therapeutics (ITRM)March 31, 2026 | msn.comWhat's going on with Iterum Therapeutics stock Monday?March 30, 2026 | msn.comIterum files wind-up petition due to limited cash, inability to raise equityMarch 27, 2026 | reuters.comIterum Therapeutics Announces Filing of Winding Up PetitionMarch 27, 2026 | globenewswire.comIterum Therapeutics (ITRM) price target increased by 63.64% to 9.18March 27, 2026 | msn.comIterum Therapeutics Provides Business UpdateFebruary 13, 2026 | globenewswire.comIterum Therapeutics PLCJanuary 17, 2026 | barrons.comIterum Therapeutics Provides Business UpdateDecember 23, 2025 | globenewswire.comIterum Therapeutics Provides Business UpdateDecember 17, 2025 | globenewswire.comIterum Therapeutics (ITRM) price target decreased by 21.43% to 5.61December 7, 2025 | msn.comIterum Therapeutics Provides Business UpdateDecember 5, 2025 | globenewswire.comIterum Therapeutics Provides Business UpdateNovember 24, 2025 | globenewswire.comIterum Therapeutics plc (NASDAQ:ITRM) Q3 2025 Earnings Call TranscriptNovember 15, 2025 | insidermonkey.comIterum Therapeutics sees cash runway into 2Q26November 14, 2025 | msn.comIterum Therapeutics sees FY26 ORLYNVAH net product sales $5M-$15MNovember 14, 2025 | msn.comIterum Therapeutics PLC (ITRM) Q3 2025 Earnings Call Highlights: Launch Success and Financial ...November 14, 2025 | finance.yahoo.comIterum Therapeutics plc (ITRM) Q3 2025 Earnings Call TranscriptNovember 14, 2025 | seekingalpha.comIterum Therapeutics Reports Third Quarter 2025 Financial ResultsNovember 14, 2025 | globenewswire.comA Glimpse of Iterum Therapeutics's Earnings PotentialNovember 14, 2025 | benzinga.comIterum Therapeutics to Report Third Quarter 2025 Financial Results on Friday, November 14, 2025November 7, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeITRM and DRRX Company DescriptionsDURECT NASDAQ:DRRXDURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.Iterum Therapeutics NASDAQ:ITRM$0.03 0.00 (0.00%) As of 06/18/2026Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Buy CrowdStrike Before the Stock Split? Here's the Case USA Today's Digital Revival Is Gaining Steam, But With Plenty of Risk Burlington Is Winning Over Shoppers But Investors Need Patience Investors Are Buying Into Sweetgreen Again—Should They? MarketBeat Week in Review – 06/15 - 06/19 Cheesecake Factory Stock Is Up Over 50%—Is There Room for More CAKE? Applied Materials Stock Looks Pricey—Can AI Demand Justify the Rally? Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
